

# HR 2802

Drug Testing Integrity Act of 2005 Congress: 109 (2005–2007, Ended)

Chamber: House

Policy Area: Crime and Law Enforcement

Introduced: Jun 8, 2005

Current Status: Referred to the Subcommittee on Commerce, Trade and Consumer Protection.

Latest Action: Referred to the Subcommittee on Commerce, Trade and Consumer Protection. (Jun 17, 2005)

Official Text: https://www.congress.gov/bill/109th-congress/house-bill/2802

### **Sponsor**

Name: Rep. Engel, Eliot L. [D-NY-17]

Party: Democratic • State: NY • Chamber: House

### **Cosponsors** (4 total)

Cosponsor	Party / State	Role	<b>Date Joined</b>
Del. Christensen, Donna M. [D-VI-At Large]	$D \cdot VI$		Jun 21, 2005
Rep. Davis, Danny K. [D-IL-7]	D·IL		Jun 21, 2005
Rep. Terry, Lee [R-NE-2]	$R \cdot NE$		Jun 28, 2005
Rep. Eshoo, Anna G. [D-CA-14]	D · CA		Sep 28, 2005

## **Committee Activity**

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 17, 2005

### **Subjects & Policy Tags**

# **Policy Area:**

Crime and Law Enforcement

#### **Related Bills**

Bill	Relationship	Last Action
109 HR 4910	Related bill	Mar 17, 2006: Referred to the Subcommittee on Commerce, Trade and Consumer Protection.

#### Summary (as of Jun 8, 2005)

Drug Testing Integrity Act of 2005 - Declares it is unlawful to: (1) knowingly manufacture, market, sell, ship, or otherwise provide to another individual any product with the intent to assist the use of such product to defraud a drug test (that is, to submit a substance that purports to be from an individual other than its actual source, or purports to have been excreted or collected other than when it was actually excreted or collected); or (2) engage in any other conduct with the intent to produce a false or misleading outcome of a test for the presence of a controlled substance.

Grants the Federal Trade Commission enforcement powers as a violation of an unfair or deceptive act or practice.

Energy and Commerce.
Energy and Commerce
Energy and Commerce
Lifergy and Committee.